

PAM Theragnostics GmbH,  
Neuendorfstraße 15B,  
16761 Hennigsdorf  
Germany

FyoniBio GmbH  
Robert-Roessle-Str. 10  
13125 Berlin  
Germany

## **PAM Theragnostics Partners with FyoniBio to Establish a Production Process for PAM's Lead Compound to prevent Alzheimer's Disease**

### **Press Release**

**Hennigsdorf / Berlin, Germany — June 2026**

**PAM Theragnostics**, a German life science start-up, and **FyoniBio**, a German expert in cell line and process development, are pleased to announce a collaboration for developing a process for the production of the glycoprotein peptidylglycine alpha-amidating monooxygenase (PAM), a promising new candidate for the prevention of Alzheimer's disease.

As a basis for the process, FyoniBio will use its versatile CHOnamite® cell line development platform, which consists of various host cell lines and allows screening of different hosts to select the most suitable cell line for the production of PAM's promising drug candidate in the desired quality and yield.

*"We are proud that PAM Theragnostics has chosen FyoniBio as its trusted partner, underscoring that our highly potent and well-established CHOnamite® cell line platform is ideally suited for complex protein formats,"* stated **Dr. Lars Stöckl**, Managing Director at FyoniBio.

*"PAM is an essential enzyme of life — one whose critical role in sustaining brain health has been underappreciated until now. Establishing a robust, scalable production process is a pivotal milestone as we advance our enzyme-replacement therapy in patients with a PAM deficiency toward the clinic. FyoniBio's deep expertise in cell line development, their proven CHOnamite® platform, and their roots right here in the Berlin-Brandenburg region make them the ideal partner to help us deliver this therapy to patients with a high risk of developing Alzheimer's disease,"* said **Dr. Andreas Bergmann**, CEO of PAM Theragnostics.

### **About PAM Theragnostics**

PAM Theragnostics is pioneering the first enzyme-replacement therapy to address PAM deficiency, a novel driver of Alzheimer's disease identified through large human population studies. Peptidylglycine alpha-amidating monooxygenase (PAM) is an essential enzyme of life that activates vital pathways in the body, among them the functioning of the blood-brain barrier. We are developing a recombinant PAM supplementation therapy to replenish enzyme levels and re-establish these essential functions. Supported by strong preclinical data demonstrating

reduced toxic protein buildup and prevention of cognitive decline, we are advancing our subcutaneously delivered lead candidate toward clinical evaluation in patients with mild cognitive impairment using a biomarker-guided approach. By restoring a core peptide-activation pathway, we aim to open a new therapeutic frontier for Alzheimer's disease and other chronic and acute neurological disorders.

Learn more at: <https://www.pam-t.com/>

### **About FyoniBio**

FyoniBio is a biologics service provider with over 15 years of scientific expertise and a proven track record of supporting more than 100 biologics projects for biotech and pharma companies worldwide. Trusted by partners whose products have reached clinical development in both FDA and EMA regions, FyoniBio offers a broad service portfolio covering the entire development chain — from cell line and process development to analytical characterization and clinical bioanalysis under GCLP.

Our team combines deep scientific understanding with flexibility and transparent communication to deliver tailored solutions that meet each project's specific needs. All services are performed under our ISO 9001–certified quality management system, ensuring full compliance with international ISO and ICH standards.

Learn more at: <https://www.fyonibio.com/>

### **Press Contacts**

Max GÖRLICH  
Chief Financial Officer, PAM Theragnostics  
[Maximilian.goerlich@pam-t.com](mailto:Maximilian.goerlich@pam-t.com)

Abdullah KARACORLUOGLU  
Business Development Manager, FyoniBio  
[abdullah.karacorluoglu@fyonibio.com](mailto:abdullah.karacorluoglu@fyonibio.com)